Contents lists available at ScienceDirect

# Heliyon



journal homepage: www.cell.com/heliyon

# Construction and validation of a nomogram based on the log odds of positive lymph nodes to predict cancer-specific survival in patients with small cell lung cancer after surgery

Ce Chao<sup>1</sup>, Kun Mei<sup>1</sup>, Min Wang, Renzhe Tang, Yongxiang Qian, Bin Wang<sup>\*</sup>, Dongmei Di<sup>\*\*</sup>

Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, China

## ARTICLE INFO

CelPress

Keywords: Log odds of positive lymph nodes Lymph node stage Nomogram SEER program Small cell lung cancer

#### ABSTRACT

Background: The lymph node ratio (LNR) is useful for predicting survival in patients with small cell lung cancer (SCLC). The present study compared the effectiveness of the N stage, number of positive LNs (NPLNs), LNR, and log odds of positive LNs (LODDS) to predict cancer-specific survival (CSS) in patients with SCLC. Materials and methods: 674 patients were screened using the Surveillance Epidemiology and End Results database. The Kaplan-Meier survival and receiver operating characteristic (ROC) curves were performed to address optimal estimation of the N stage, NPLNs, LNR, and LODDS to predict CSS. The optimal LN status group was incorporated into a nomogram to estimate CSS in SCLC patients. The ROC curve, decision curve analysis, and calibration plots were utilized to test the discriminatory ability and accuracy of this nomogram. Results: The LODDS model showed the highest accuracy compared to the N stage, NPLNs, and LNR in predicting CSS for SCLC patients. LODDS, age, sex, tumor size, and radiotherapy status were included in the nomogram. The results of calibration plots provided evidences of nice consistency. The ROC and DCA plots suggested a better discriminatory ability and clinical applicability of this nomogram than the 8th TNM and SEER staging systems. Conclusions: LODDS demonstrated a better predictive power than other LN schemes in SCLC patients after surgery. A novel LODDS-incorporating nomogram was built to predict CSS in SCLC patients after surgery, proving to be more precise than the 8th TNM and SEER staging.

# 1. Introduction

Lung cancer is a common malignant cancer and accounts for a large proportion of cancer-related mortality worldwide [1]. Small cell lung cancer (SCLC) accounts for 14% of lung cancer cases [2]. In the classification of lung cancer, SCLC is a neuroendocrine lung

# https://doi.org/10.1016/j.heliyon.2023.e18502

Received 6 March 2023; Received in revised form 13 July 2023; Accepted 19 July 2023

Available online 22 July 2023

<sup>\*</sup> Corresponding author. Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, No.185, Juqian Street, Tianning District, Changzhou, 213003, Jiangsu Province, China.

<sup>\*\*</sup> Corresponding author. Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, No.185, Juqian Street, Tianning District, Changzhou, 213003, Jiangsu Province, China.

E-mail addresses: colin\_iverson@163.com (B. Wang), ddm5122@163.com (D. Di).

<sup>&</sup>lt;sup>1</sup> These authors have contributed equally to this work.

<sup>2405-8440/© 2023</sup> The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

tumor with a poor prognosis [3]. Comprehensive treatment of SCLC includes surgery, radiotherapy, and chemotherapy. The patients with SCLC are sensitive to chemoradiotherapy in the early treatment of SCLC [4]. Systemic platinum-based chemotherapy either combined with concurrent radiotherapy or alone may be a potentially curative treatment for SCLC [4]. However, treatment resistance and relapse are the ultimate causes of death. Surgery is the main method of cancer treatment, although a previous trial has demonstrated that radiotherapy resulted in a better prognosis than surgery for SCLC patients before the 1970s [5]. In-depth research has allowed patients with stage I–II and even stage III N2 SCLC to be regarded as a surgical evaluation population [6–9]. Multiple studies have shown that the management of surgery can prolong the survival time of early-stage SCLC patients compared to those treated with concurrent chemoradiation [10,11].

At present, the Veterans Administration Lung Study Group (VALSG) two-stage classification scheme is widely used to define the degree of the disease in SCLC patients [12]. However, the tumor–node–metastasis (TNM) system has been recommended to replace the VALSG staging system [13]. The lymph node (LN) status plays a vital role in surgery and prognosis assessment [14]. Recently, more and more evidences have demonstrated that the log odds of positive LNs (LODDS), defined as the logarithmic odds of the number of positive and negative LNs, can predict the prognosis better than other LN schemes for multiple malignancies, including medullary thyroid carcinoma [15], lung squamous cell carcinoma [16], oral squamous cell carcinoma [17], esophageal squamous cell carcinoma [18], and pancreatic cancer [19]. However, LODDS was not the same result in prognosis in SCLC patients [21,22]. To date, there have been no data screening the most appropriate alternative LN scheme in cases with resectable SCLC. The present study compared the effectiveness of the N stage, number of positive LNs (NPLNs), LNR, and LODDS to predict cancer-specific survival (CSS) in SCLC patients and generated a novel nomogram to predict the prognosis based on an optimal LN scheme in cases with resectable SCLC.

# 2. Materials and methods

# 2.1. Study population

Patients with the first primary SCLC were selected from the Surveillance Epidemiology and End Results (SEER) Research Plus Data 18 population-based registries. They provided some clinicopathological data, including age at diagnosis, race, year of diagnosis, sex, primary site, TNM stage, histological tumor type, nuclear grade, surgical methods used, chemotherapy status, radiation therapy status, tumor size, CSS time, and survival month. According to the SEER database, the endpoint of cases is death from lung cancer or time of last contact. And, the start of follow-up is date of cancer diagnosis. Therefore, CSS time was defined as the time from lung cancer diagnosis to death from lung cancer. OS time was defined as the time from lung cancer diagnosis to death from lung cancer. OS time was defined as the time from lung cancer diagnosis to death. 73,683 patients were the first primary SCLC in the SEER database between 2004 and 2018. Eligible patients were included according to the following inclusion criteria: (1) patients diagnosed with SCLC (code: 8041/3–8045/3) by positive histology without previous history of tumors in 2004–2018; (2) surgery (code: 21, 22, 25, 30–70) and LNs were removed; and (3) age over 18 years. The exclusion criteria were as follows: (1) without enough clinical data (unknown age, race, primary site, radiotherapy status, tumor size, nuclear grade, number of lymph node, and survival time); (2) died within one month after surgery (survival time was 0); (3) patients with advanced small-cell lung cancer who are not candidates for surgery (disease was at stage N3 or M1). The flowchart of screening is shown in Fig. 1. Since the study utilized the database's anonymous data, it was not necessary to obtain the institutional review board's approval or individual patient consent. The TNM information was re-grouped based on the AJCC 8th TNM staging.



Fig. 1. The flowchart of screening the applicable patients with SCLC from SEER database. SEER, the Surveillance, Epidemiology and End Results.

Table 1	
The clinical and pathological characteristics of the final cohort, the training	set, and the testing set.

BeakUnitable </th <th>Characteristics</th> <th>Total (N = 674)</th> <th>Training set (N = 471)</th> <th>Testing set (N <math>=</math> 203)</th> <th>P-value</th>	Characteristics	Total (N = 674)	Training set (N = 471)	Testing set (N $=$ 203)	P-value
Black White Other41 (87)8 (3.9)White Other09(0-2)12 (2.5)5 (2.5)Other12 (2.5)5 (2.5)1.9Set2.6 (6.5.)1.0 (6.7.)1.9Set2.6 (6.5.)1.0 (8.7.)1.0 (8.7.)Set2.6 (6.5.)1.0 (8.7.)7 (8.8.)1.0 (8.7.)Set2.7 (8.7.)1.0 (8.7.)7 (8.8.)1.0 (8.7.)Set1.0 (8.7.)1.0 (8.7.)7 (8.8.)1.0 (8.7.)Set1.0 (1.5.)1.0 (1.6.)2.0 (1.6.)1.0 (1.6.)Set1.0 (1.5.)2.0 (1.6.)2.0 (1.6.)1.0 (1.6.)Set1.0 (1.6.)1.0 (1.6.)1.0 (1.6.)1.0 (1.6.)Set	Race				0.091
Whene148 (a88.)100 (39.)Other76.31.2 G.39.0 (4.3)9.0 (4.3)See300 (4.5.)26 (4.5.)1.0 (4.3.)9.0 (4.3.)Alage ora20.0 (4.5.)1.0 (4.9.)9.0 (4.3.)9.0 (4.3.)Alage ora4.5 (6.1.0)20.0 (6.3.)1.0 (4.9.)9.0 (4.0.)Controlo et al.1.5 (7.1.1)8.1 (7.2.0)1.0 (7.0.0)1.0 (7.0.0)Now robe, right11.0 (6.5.)9.0 (6.3.)1.0 (7.0.0)1.0 (7.0.0)Midde ble, right20.0 (3.0.0)1.0 (2.7.0)0.0 (3.0.0)1.0 (7.0.0)Midde ble, right20.0 (3.0.0)1.0 (2.7.0)0.0 (3.0.0)1.0 (7.0.0)Midde ble, right20.0 (3.0.0)1.0 (2.7.0)0.0 (3.0.0)1.0 (7.0.0)Upper lobe, right20.0 (3.0.0)1.0 (2.7.0)0.0 (3.0.0)1.0 (7.0.0)Midde ble, right20.0 (3.0.0)1.0 (2.7.0)0.0 (3.0.0)1.0 (7.0.0)Upper lobe, right20.0 (3.0.0)1.0 (3.0.0)1.0 (7.0.0)1.0 (7.0.0)Contro20.0 (3.0.0)1.0 (2.7.0)1.0 (3.0.0)1.0 (7.0.0)Contro20.0 (3.0.0)20.0 (3.0.0)1.0 (7.0.0)1.0 (7.0.0)Contro20.0 (3.0.0)1.0 (3.0.0)1.0 (7.0.0)1.0 (7.0.0)Contro20.0 (3.0.0)20.0 (3.0.0)1.0 (7.0.0)1.0 (7.0.0)Contro20.0 (3.0.0)20.0 (3.0.0)1.0 (7.0.0)1.0 (7.0.0)Contro20.0 (3.0.0)20.0 (3.0.0)1.0 (7.0.0)1.0 (7.0.0)Contro20.0	Black	49 (7.3)	41 (8.7)	8 (3.9)	
Other71 (2.5)12 (2.5)13.(5.7).0.39Sex	White	608 (90.2)	418 (88.7)	190 (93.6)	
SeeUseUse (5.7)Use (5.	Other	17 (2.5)	12 (2.5)	5 (2.5)	
Fende369 (54.7)266 (66.5)103 (50.7)103 (50.7)Age groupC 56 years29 (38.4)109 (38.2)90 (38.9).2 65 years29 (38.4)201 (0.18)21 (0.1.9).2 65 years115 (7.1.9)70 (6.8)23 (15.8).2 65 years107 (7.1.9)70 (6.8)23 (15.8).1 70 (7.1.9)70 (6.8)23 (15.8)1 70 (7.1.9)70 (6.8)23 (15.8)1 70 (7.1.9)10 (5.9)27 (7.1.9)64 (3.1.9)1 70 (7.1.9)10 (5.9)27 (7.1.9)13 (2.9)2 3 cm240 (3.6.3)20 (24.1)13 (25.9)2 3 cm20 (3.4.1)13 (2.3.2)10 (6.9.1)1 70 (7.1.9)13 (12.9)10 (7.2.1)13 (16.9)70 (7.9.1)1 71 (7.1.9)13 (12.9)10 (7.2.1)13 (16.7)10 (7.1.9)1 71 (7.1.9)13 (12.9)10 (7.2.1)10 (7.1.9)10 (7.1.9)1 71 (7.1.9)13 (12.9)10 (7.2.1)10 (7.1.9)10 (7.1.9)1 71 (7.1.9)13 (12.9)10 (7.2.1)10 (7.1.9)10 (7.1.9)1 71 (7.1.9)10 (7.2.1)10 (7.2.1)10 (7.1.9)10 (7.1.9)	Sex				0.198
<table-container>Male305 (45.)90 (48.)90 (48.)9455 years29 (38.4)180 (08.2)79 (38.9)74 (46.7)455 years15 (61.6)181 (7.2)44 (16.7)74 (16.7)Locari forie115 (17.1)81 (7.2)32 (15.8)74 (16.7)Lower kole, hight115 (17.1)97 (16.8)32 (15.8)75 (16.7)Lower kole, hight10 (63.0)140 (23.7)64 (31.5)75 (16.7)Upper kole, right98 (28.4)140 (23.7)85 (28.6)75 (16.7)Upper kole, right98 (28.4)140 (23.7)85 (28.6)75 (16.7)23 cm04 (63.0)32 (16.1)13 (16.2)71 (15.0)75 (16.7)23 cm16 (16.4)34 (72.1)14 (16.9)75 (16.7)75 (16.7)17 Cm48 (7.4)34 (72.1)14 (16.9)75 (17.9)76 (17.9)18 Cm13 (16.8)74 (19.3)74 (19.7)76 (19.7)76 (19.7)18 Cm13 (16.8)76 (19.7)76 (19.7)76 (19.7)76 (19.7)18 Cm13 (16.8)76 (19.7)76 (19.7)76 (19.7)76 (19.7)19 Cm13 (16.8)76 (19.7)76 (19.7)76 (19.7)76 (19.7)19 Cm13 (16.8)76 (19.7)76 (19.7)76 (19.7)76 (19.7)19 Cm10 (10.7)10 (10.7)76 (19.7)76 (19.7)76 (19.7)10 Cm10 (10.7)10 (10.7)10 (10.7)76 (19.7)76 (19.7)10 Cm10 (10.7)10 (10.7)10 (10.7)76 (19.7)&lt;</table-container>	Female	369 (54.7)	266 (56.5)	103 (50.7)	
Age group	Male	305 (45.3)	205 (43.5)	100 (49.3)	
55 years259 (38.4)180 (38.2)79 (38.7)79 (38.7)565 years155 (0.1.8)124 (0.1.1)0.44Locariolos, right115 (17.1)81 (17.2)34 (16.7)0.41Lower loke, right110 (15.5)79 (16.8)32 (15.8)10.1Mathe broch, right10 (15.3)40 (0.2)64 (0.1.5)10.1Mathe broch, right20 (60.3)16 (0.2)10.110.1Mathe broch, right104 (20.3)10 (0.2)64 (0.1.5)10.1Joper Iole, right104 (20.3)10 (0.2)10.20.9123 cm20 (36.1)10 (23.7)10 (25.0)10.123 cm43 (16.6)20 (24.1)132 (26.6)0.7023 cm43 (16.6)20 (24.1)132 (26.6)0.7024 (17.1)14 (7.2)14 (6.6)0.700.7016 (11.1)133 (10.1)14 (20.6)0.700.7017 (17.2)20 (17.1)10 (17.2)0.710.7118 (11.1)13 (16.8)17 (17.9)10.11.7119 (11.1)13 (16.8)10 (17.2)30 (17.7)0.7319 (11.1)13 (16.4)10 (17.2)30 (17.7)1.7110 (11.1)13 (14.6)10 (17.2)1.710.7310 (11.1)13 (14.6)10 (17.2)1.711.7110 (11.1)13 (16.8)10 (17.2)1.711.7110 (11.1)13 (16.8)10 (17.2)1.711.7111 (11.1)13 (16.8)10 (17.2)1.71	Age group				0.932
<table-container>≥65 years415 (0.5)220 (0.8)124 (0.1)</table-container>	<65 years	259 (38.4)	180 (38.2)	79 (38.9)	
LoceInterfaceInterfaceInterfaceLower loke, fight111 (16.5)79 (16.8)32 (15.8)Lower loke, fight10 (15.5)40.8332 (15.7)Middle loke, right36 (5.3)27 (5.7)9 (4.4)Upper loke, fight30 (3.3)140 (22.7)56 (23.6)Upper loke, fight198 (29.4)120 (25.6)198 (29.7)Samo240 (35.6)196 (35.2)7 (35.0)Tumor size	$\geq$ 65 years	415 (61.6)	291 (61.8)	124 (61.1)	
Lower loke, left115 (17.)81 (17.2)94 (16.7)94 (16.7)Main broaches10 (1.5)4 (0.8)6 (3.0)1Mini broaches10 (1.5)4 (0.8)6 (3.0)1Upper loke, left20 (30.3)140 (23.7)6 (23.6)6 (3.0)Upper loke, left20 (30.3)140 (23.7)6 (23.6)6 (3.0)2 send4 (9 (35.7)12 (45.6)6 (3.0)6 (3.0)2 send4 (4 (3.1)12 (45.6)6 (3.0)6 (3.0)2 send4 (4 (3.1)13 (4 (3.2)10 (6 (3.2)6 (3.0)1 H4 (15.6)23 (44.5)10 (6 (3.2)6 (3.0)1 H4 (5 (5.1)13 (3 (2.5)7 (7 (7.9)6 (3.0)1 H13 (16.8)7 (16.8)3 (16.7)6 (3.0)6 (3.0)1 H13 (17.1)13 (17.2)3 (16.7)1 (16.4)7 (3.4)1 H14 (3 (2.1)11 (7 (2.7)3 (16.7)1 (16.4)1 H3 4 (40.6)3 (8.1)16 (7.2)1 (16.4)1 H4 (16.5)29 (44.4)10 (6 (2.2)1 (16.4)1 H4 (16.5)29 (44.4)10 (6 (2.2)1 (16.4)1 H5 (5 (7.1)1 (5 (3.1)1 (5 (3.1)1 (16.4)1 H5 (5 (7.1)1 (5 (3.1)1 (5 (3.1)1 (5 (3.1)1 H5 (5 (7.4)3 (10.4)3 (10.1)1 (10.1)1 H5 (5 (3.1)5 (3.1)1 (5 (3.1)1 (5 (3.1)1 H5 (3.1)1 (3 (3.0)1 (3 (3.0)1 (3 (3.0)1 H	Location site				0.414
Lower body, right111 (16.5)?P (16.8)?P (16.8)?P (16.8)Midde lode, right30 (3.3)140 (23.7)9 (4.4)Upper lode, right30 (3.3)140 (23.7)58 (2.8.0)Upper lode, right198 (2.9.4)100 (23.7)58 (2.8.0)Sam434 (6.4.1)302 (6.4.1)132 (6.5.0)67 (6.5.0)Tumor size	Lower lobe, left	115 (17.1)	81 (17.2)	34 (16.7)	
Main branches10 (1.5)4 (0.8)6 (3.0)Upper loke, right36 (5.3)27 (5.7)9 (4.4)Upper loke, right198 (20.4)140 (29.7)64 (3.5)Tumor siz	Lower lobe, right	111 (16.5)	79 (16.8)	32 (15.8)	
Midde tole, right36 (3.3)27 (5.7)9 (4)Upper loke, right198 (29.4)140 (29.7)64 (31.5)Upper loke, right198 (29.4)140 (29.7)64 (31.5)Cana240 (35.6)180 (55.6)71 (35.0)Cana240 (35.6)169 (35.9)71 (35.0)Cana240 (35.6)238 (49.5)14 (6.9)Upper loke, right31 (50.6)238 (49.5)18 (53.2)Till34 (50.6)238 (49.5)81 (39.9)Till34 (50.6)238 (49.5)16 (57.1)IA200 (34.1)15 (32.5)77 (37.9)IB13 (16.8)70 (37.9)16 (57.1)IB50 (7.4)31 (70.2)16 (57.1)IB15 (17.1)81 (17.2)16 (16.7)IBA15 (17.1)81 (17.2)16 (16.7)IBA14 (32.1)10 (22.7)36 (17.7)IBA15 (17.1)81 (17.2)16 (57.1)IBA15 (17.1)81 (17.2)16 (57.1)IBA15 (17.1)81 (17.2)16 (57.1)IBA16 (40.6)28 (48.4)16 (57.1)ISA44 (40.6)28 (48.4)16 (57.1)ISA16 (40.6)11 (54.1)20.1ISA16 (40.6)10 (17.1)ISA16 (40.6)10 (17.1)ISA16 (57.1)10 (37.1)ISA16 (30.1)10 (37.1)ISA16 (30.1)10 (37.1)ISA16 (30.1)10 (37.1)ISA16 (30.1)10 (30.1)<	Main bronchus	10 (1.5)	4 (0.8)	6 (3.0)	
Upper bok, ridt204 (30.3)140 (29.7)64 (31.5)Upper bok, ridt198 (28.4)(0.89)Upper bok, ridt198 (28.4)(0.89)Site Zamo240 (35.6)122 (65.0)(0.89)23 cm240 (35.6)109 (35.9)(15.5)24 cm240 (35.6)109 (35.9)(16.6)Crade14 (7.2)14 (6.9)(6.79)U143 (15.6)233 (42.5)108 (53.2)(16.79)U143 (15.6)233 (42.5)71 (37.9)(16.4)IA230 (34.1)153 (32.5)71 (37.9)(16.4)IB113 (15.6)79 (16.6)34 (16.7)(16.7)IB23 (34.1)153 (32.5)71 (36.3)(16.7)IB23 (34.1)163 (38.1)17 (36.3)(16.7)IB23 (34.1)16 (38.1)16 (7.9)(16.1)IB23 (34.1)13 (38.1)16 (7.9)(16.1)IB23 (34.1)13 (38.1)16 (7.9)(16.1)IB24 (35.6)29 (44.4)105 (51.7)(20.3)IB25 (20.1)96 (20.4)105 (20.1)(20.3)IB15 (20.1)96 (20.4)137 (67.5)(37.9)IB15 (20.1)15 (20.1)96 (20.4)137 (67.5)(37.9)IB15 (20.1)15 (20.1)101 (21.4)102 (21.4)(20.2)IB15 (20.1)15 (20.1)101 (21.4)102 (21.4)(20.2)IB15 (20.1)15 (20.1)15 (20.1)(20.2)IB <t< td=""><td>Middle lobe, right</td><td>36 (5.3)</td><td>27 (5.7)</td><td>9 (4.4)</td><td></td></t<>	Middle lobe, right	36 (5.3)	27 (5.7)	9 (4.4)	
Ipper table right194 (9.7)194 (9.7)194 (9.7)194 (9.7)	Upper lobe, left	204 (30.3)	140 (29.7)	64 (31.5)	
Tuno trate(0.2)3 cm3/3 (0.6)0.2) (0.5)0.2) (0.5)0.2)0.2)2 d cm4/1 (0.6)2.33 (4.9)0.8) (3.9)0.8)114/1 (0.6)2.33 (4.9)0.8) (3.9)0.8)1213/1 (0.6)2.33 (4.9)0.8) (3.9)0.8)1313/1 (0.6)2.33 (4.9)0.8) (3.9)0.8)1313/1 (0.6)1.5) (2.5)7.7)0.8)1413/1 (0.6)1.5) (2.5)7.7)0.8)151.3) (1.6)1.5) (2.7)3.4) (1.6)0.8)161.3) (1.6)1.6) (2.7)3.4) (1.6)0.8)172.3 (3.4)1.8) (3.2)1.6) (2.7)0.8)181.5) (2.7)1.6) (3.8)0.6) (2.7)0.7)181.5 (7.1)1.8) (3.8)0.6) (7.9)0.7)181.5 (7.1)1.8) (3.8)0.6) (7.9)0.7)183.4 (4.6)2.20 (4.4)1.6 (7.9)0.7)173.4 (4.6)2.20 (4.4)1.6 (7.9)0.7)183.4 (4.6)2.00 (4.4)1.6 (7.9)0.1)174.6 (3.5)2.60.7)0.101.6183.4 (4.6)2.00 (4.4)1.6 (7.9)0.1)0.1)191.5 (7.6)2.6 (4.8)0.9 (9.2)0.1)0.1)101.5 (7.6)2.6 (4.8)0.9 (9.2)0.1)0.1)101.6 (2.0)3.6 (6.9)1.6 (3.1)0.1)0.1)101.6 (2.0)3.6 (6.1)<	Upper lobe, right	198 (29.4)	140 (29.7)	58 (28.6)	0.001
<3 m40 (49.4)30 (94.1)10 (19.1)10 (19.1)3 m240 (35.0)16 (35.2)7 (35.0)6.70Grade240 (45.3)24 (40.2)10 (6.3.2)7 (35.0)III245 (42.3)20 (44.3)18 (39.9)6.71III25 (42.3)20 (44.3)18 (39.9)7 (35.7)TM53 (32.5)7 (37.7)7 (37.7)7 (37.7)IB10 (10.6)9 (16.8)34 (16.7)7 (37.7)IB10 (17.2)10 (17.2)36 (17.7)7 (37.7)IIIA10 (17.2)10 (17.2)36 (17.7)7 (37.7)IIIA10 (17.2)10 (17.2)36 (17.7)7 (37.7)IIIA143 (21.2)10 (7 (22.7)36 (17.7)7 (37.7)IIIA143 (21.2)10 (7 (22.7)36 (17.7)7 (37.7)IIIA143 (21.2)10 (7 (22.7)10 (5 (21.7)7 (37.7)IIIA143 (21.2)17 (7 (6.3)10 (6 (17.1)7 (37.7)IIIA35 (45.0)38 (8.1)16 (7.9)7 (37.7)IIIA34 (49.6)20 (44.4)105 (1.7)7 (37.7)IIIA15 (20.0)36 (8.1)16 (7.9)7 (37.7)IIIA13 (40.6)20 (44.4)105 (1.7)7 (37.7)IIIA13 (40.6)20 (41.4)105 (1.7)IIIA13 (40.6)36 (20.1)10 (31.6)10 (31.6)IIIA14 (16.7)10 (21.4)10 (21.6)10 (21.6)IIIA15 (76.1)10 (21.6)10 (21.6)10 (21.6) <tr< td=""><td>Tumor size</td><td></td><td>000 (( 1 1)</td><td>100 ((5.0)</td><td>0.891</td></tr<>	Tumor size		000 (( 1 1)	100 ((5.0)	0.891
2 S m24 (1955)10 (1953)1 (1950)10 (1950)	<3 cm	434 (64.4)	302 (64.1)	132 (65.0)	
distribution:distribution:Introduction:distribution:ITT(4.6.9.)INT(4.6.2.)INT(4.6.2.)INT(4.6.2.)INT	≥3 cm	240 (35.6)	169 (35.9)	71 (35.0)	0.670
Juli341 (50)341 (52)10 (53.2)III341 (50,6)233 (49.5)108 (53.2)IV283 (42.3)233 (49.5)108 (53.2)IV233 (49.5)108 (53.2)10.5IAA133 (16.5)79 (16.6)34 (16.7)IAA133 (16.5)79 (16.6)34 (16.7)IBA115 (17.1)81 (7.2)34 (16.7)IBA15 (17.1)81 (7.2)34 (16.7)IBA15 (17.1)81 (7.2)34 (16.7)IBA15 (17.1)81 (7.2)34 (16.7)IBA15 (17.1)81 (7.2)34 (16.7)IBA33 (49.6)18 (3.8)5 (2.5)T33 (49.6)28 (8.1)10 (5 (5.7)T2241 (35.6)171 (36.3)70 (34.5)T345 (8.7)34 (7.2)11 (5.4)T445 (8.7)258 (54.8)96 (47.3)Iccalized34 (46.5)258 (54.8)96 (7.3)Iccalized34 (46.5)258 (54.8)96 (19.2)Iccalized34 (46.5)258 (54.8)96 (19.2)Iccalized34 (46.5)258 (54.8)96 (19.2)Iccalized34 (6.7)11 (6.3)10 (7.8)Iccalized34 (6.7)18 (3.8)6 (3.0)Iccalized155 (7.4)357 (75.8)16 (53.1)Icbetromy43 (6.7)15 (6.3).1)6 (32.5)Icbetromy24 (3.6)16 (3.6)11 (6.9)Icbetromy24 (3.6)16 (3.6)10 (2.1)No21 (6.2,3)10 (2.1,	Grade	40 (7.1)	04 (7.0)	14(( 0)	0.670
Ind31 (30.9)235 (49.3)100 (53.2)IV285 (42.3)204 (43.3)81 (39.9)		48 (7.1)	34 (7.2) 222 (40 E)	14 (6.9)	
IVJoint (3.5)Joint (3.5)Joint (3.5)TNM		341 (50.6)	233 (49.3)	108 (55.2)	
IAn      0.549        IA      230 (34.1)      153 (32.5)      7 (37.9)        IB      131 (16.8)      79 (16.8)      34 (16.7)        IBA      150 (7.4)      31 (7.0)      17 (8.4)        IBB      143 (21.2)      107 (22.7)      36 (17.7)        IIBA      143 (21.2)      107 (22.7)      36 (17.7)        IIBA      133 (49.6)      128 (48.1)      106 (52.2)        T      71      35 (67.7)      70 (34.5)        T2      214 (35.8)      17 (36.3)      16 (7.9)        T3      54 (8.0)      38 (8.1)      16 (7.9)        T4      45 (67.7)      38 (47.2)      11 (54.1)        Casilization      54 (46.0)      204 (44.2)      105 (51.7)        T3      54 (52.5)      258 (54.8)      96 (47.3)      105 (7.1)        Localized      314 (46.6)      204 (41.0)      105 (7.7)      105 (7.8)        Sublobectomy      135 (76.0)      86 (20.4)      39 (19.2)      105 (7.8)        Patemanoctomy      135 (76.8)      139 (7.5)      105 (7.8)        Sublobectomy      13		285 (42.3)	204 (43.3)	81 (39.9)	0 5 4 4
IA  2.50 (24.1)  1.53 (22.3)  74 (3.7.9)    IB  113 (16.8)  79 (16.8)  14 (16.7)    IIA  15 (07.4)  81 (07.2)  34 (16.7)    IIB  115 (17.1)  81 (17.2)  36 (17.7)    IIB  23 (3.4)  18 (3.8)  5 (2.5)    T  23 (4.9.6)  18 (3.8)  70 (3.4.5)    T1  34 (49.6)  28 (48.4)  106 (52.2)    T2  241 (35.8)  17 (36.3)  70 (34.5)    T4  45 (6.7)  34 (7.2)  11 (5.4)    Esgenal  54 (8.0)  38 (8.1)  105 (51.7)    Ioalized  314 (46.6)  209 (44.4)  105 (51.7)    Ioalized  314 (46.6)  209 (44.4)  105 (51.7)    Ioalized  314 (46.6)  209 (44.4)  105 (7.8)    Subjectomy  315 (76.4)  35 (75.8)  66 (7.3)    Ioalized  314 (46.6)  302 (64.1)  137 (67.5)    Subjectomy  315 (76.4)  35 (75.8)  15 (77.8)    Paeumoactomy  21 (3.5)  15 (3.3.1)  62 (30.5)    Yes  25 (34.9)  16 (9 (35.9)  16 (6.3.9)    No  13 (20.3)  105 (3.1.1)  62 (30.5)    Yes  45 (6.7)  315 (66.1) </td <td></td> <td>220 (24 1)</td> <td>1E2 (22 E)</td> <td>77 (27 0)</td> <td>0.344</td>		220 (24 1)	1E2 (22 E)	77 (27 0)	0.344
ID15 (10.50)5 (10.53)5 (10.57)(10.64)IIA50 (7.4)33 (7.0)17 (8.4)IIB115 (17.1)81 (17.2)34 (16.7)IIB13 (21.2)107 (22.7)36 (17.7)IIB23 (3.4)18 (3.8)5 (2.5)IIB23 (3.4)18 (3.8)5 (2.5)T1354 (49.6)228 (48.4)106 (52.2)T2241 (35.8)17 (36.3)70 (34.5)T445 (6.7)38 (8.1)16 (7.9)T445 (6.7)34 (7.2)11 (5.4)T445 (6.7)268 (54.8)96 (47.3)Coalized314 (46.6)209 (44.4)105 (51.7)Distant6 (0.9)4 (0.8)2 (1.0)Subobectomy155 (20.0)96 (20.4)35 (19.2)Subobectomy155 (20.0)96 (20.4)35 (19.2)Chemotherapy24 (3.6)18 (3.8)6 (3.0)Ration13 (20.3)15 (25.9)15 (76.9)No439 (65.1)302 (64.1)137 (67.5)Yes450 (67.7)15 (69.9)14 (16.9.5)No137 (20.3)10 (21.4)36 (17.7)No12 (23.4)10 (23.4)14 (0.2)No458 (65.7)258 (64.1)137 (67.5)No137 (20.3)10 (21.4)36 (17.7)No258 (57.7)156 (69.7)15 (69.9)No13 (20.7)15 (20.1)15 (20.1)No258 (61.1)137 (67.5)15 (10.1)No258 (61.3)10 (21.4) </td <td>IR</td> <td>230 (34.1)</td> <td>70 (16 8)</td> <td>77 (37.9) 34 (16 7)</td> <td></td>	IR	230 (34.1)	70 (16 8)	77 (37.9) 34 (16 7)	
Inf      50 (7.4)      50 (7.4)      10 (0.4)        IB      115 (71.1)      81 (17.2)      36 (17.7)        IIIA      143 (21.2)      107 (22.7)      36 (17.7)        IIIB      23 (3.4)      18 (3.8)      52 (2.5)        T stage		50(74)	22 (7 0)	17(94)	
Ind      10 (17)      10 (17)      10 (17)        IIIA      143 (21,2)      10 (7 (22,7)      36 (17.7)        IIIB      23 (3.4)      18 (3.8)      5 (2.5)        IIIA      33 (49.6)      228 (48.4)      106 (52.2)      7        T1      33 (49.6)      38 (8.1)      16 (7.9)      7        T4      45 (6.7)      38 (7.2)      11 (5.4)      7        Distant      6 (0.9)      4 (0.8)      2 (1.0)      7        Distant      51 (7.6, 4)      39 (19.2)      7      7        Subiobectomy      135 (20.0)      9 (20.4)      39 (19.2)      7        Paeumonetomy      24 (3.6)      138 (38.3)      6 (3.0)      7        No      39 (65.1)      30 (2 (6.1)      137 (67.5)      7      7        Netomy      24 (6.5.7)      315 (66.9)      14 (16.9.5) <t< td=""><td>IIB</td><td>115(171)</td><td>81 (17 2)</td><td>34 (16 7)</td><td></td></t<>	IIB	115(171)	81 (17 2)	34 (16 7)	
IIIB2) (Ab.18 (3.8)5 (2.5)T stage	IIIA	143 (21.2)	107(22.7)	36 (17.7)	
Targe      0.743        T1      334 (49.6)      28 (48.4)      106 (52.2)        T2      241 (35.8)      171 (36.3)      70 (34.5)        T3      54 (8.0)      38 (8.1)      16 (7.9)        T4      45 (6.7)      34 (7.2)      11 (5.4)        SEER Stage      .      0.203        Regional      354 (52.5)      258 (54.8)      96 (47.3)        Localized      14 (46.6)      209 (44.4)      105 (51.7)        Distant      6 (0.9)      4 (0.8)      2 (1.0)        Surgery      .      0.789        Sublobectomy      135 (20.0)      96 (20.4)      39 (19.2)        Lobectomy      135 (20.0)      96 (20.4)      39 (19.2)        Lobectomy      215 (76.4)      35 (75.8)      136 (7.8)        Pneumonectomy      24 (36.5)      137 (67.5)      .        Yes      235 (34.9)      169 (35.9)      6 (32.5)      .        Yes      245 (67.7)      315 (66.9)      141 (69.5)      .        No      218 (32.3)      15 (67.9)      141 (69.5)      .	IIIB	23 (3 4)	18 (3.8)	5 (2.5)	
The and Bill334 (49.6)228 (48.4)106 (52.2)100 (52.2)T2241 (35.8)171 (36.3)70 (34.5)T354 (8.0)38 (8.1)16 (7.9)T445 (6.7)34 (7.2)11 (5.4)FEER Stage	T stage	20 (01)	10 (010)	0 (210)	0.743
T2      A41 (35.8)      T71 (36.3)      70 (34.5)        T3      54 (8.0)      38 (8.1)      16 (7.9)        T4      45 (6.7)      34 (7.2)      11 (5.4)        SEER Stage	T1	334 (49.6)	228 (48.4)	106 (52.2)	
T354 (8.0)38 (8.1)16 (7.9)T445 (6.7)34 (7.2)11 (5.4)T445 (6.7)34 (7.2)11 (5.4)PERR Stage	T2	241 (35.8)	171 (36.3)	70 (34.5)	
T4    45 (6.7)    34 (7.2)    11 (5.4)      SEER	Т3	54 (8.0)	38 (8.1)	16 (7.9)	
SEER stage      0.203        Regional      354 (52.5)      258 (54.8)      96 (47.3)        Localized      41 (46.6)      209 (44.4)      105 (51.7)        Distant      6 (0.9)      4 (0.8)      2 (1.0)        Surgery	T4	45 (6.7)	34 (7.2)	11 (5.4)	
Regional      S54 (52.5)      258 (54.8)      96 (47.3)        Localized      314 (46.6)      209 (44.4)      105 (51.7)        Distant      6 (0.9)      4 (0.8)      21.0)        Surgery	SEER Stage				0.203
Localized314 (46.6)209 (44.4)105 (51.7)Distant6 (0.9)4 (0.8)2 (1.0)Surger	Regional	354 (52.5)	258 (54.8)	96 (47.3)	
Distant      6 (0.9)      4 (0.8)      2 (1.0)        Surgery      .       Net  <	Localized	314 (46.6)	209 (44.4)	105 (51.7)	
Surgery	Distant	6 (0.9)	4 (0.8)	2 (1.0)	
Subolectomy      135 (20.0)      96 (20.4)      39 (19.2)        Lobectomy      515 (76.4)      357 (75.8)      158 (77.8)        Pneumonecomy      43 (3.6)      18 (3.8)      6 (3.0)        Radiation      37 (67.5)      6 (30.2)        Yes      39 (51.1)      302 (64.1)      137 (67.5)        Yes      325 (34.9)      156 (33.1)      6 (32.5)        Chemotherapy      55 (33.1)      6 (30.5)      55 (30.1)        Yes      6 (67.7)      315 (65.9)      16 (9.5)        Yes      6 (67.7)      315 (65.9)      137 (67.5)        Nage      137 (20.3)      101 (21.4)      36 (17.7)        N1      137 (20.3)      101 (21.4)      36 (17.7)        N2      117 (14.9)      87 (18.5)      30 (14.8)        NPLN1      137 (20.3)      101 (21.4)      139 (68.5)        NPLN2      151 (22.4)      110 (23.4)      139 (68.5)        NPLN3      155 (21.1)      10.24      110 (23.4)        NPLN3      131 (63.9)      92 (62.0)      139 (68.5)        NPLN2      131 (19.7)      92 (10	Surgery				0.789
Lobectomy      515 (76.4)      357 (75.8)      158 (77.8)        Pneumonectomy      24 (36)      18 (3.8)      6 (3.0)        Radiation      18 (3.8)      137 (67.5)      0.451        No      439 (65.1)      302 (64.1)      137 (67.5)      0.571        Yes      235 (34.9)      169 (35.9)      66 (32.5)      0.571        Chemotherapy      55 (33.1)      62 (30.5)      0.571        No      245 (67.7)      315 (66.9)      141 (69.5)      0.190        Natage      24 (30.6)      137 (67.5)      0.190      0.190        N1      37 (20.3)      101 (21.4)      36 (17.7)      0.190        N2      170 (7.4)      87 (85.5)      0.14.8)      0.188        NPLN      103 (20.3)      101 (21.4)      36 (17.7)      0.188        NPLN      117 (17.4)      87 (85.5)      0.14.8)      0.14.8)        NPLN      28 (60.5)      139 (60.5)      0.14.8)      0.14.8)        NPLN      29 (10.1)      10 (23.4)      13 (10.2)      1.16.2)        NPLN3      95 (14.1)      29 (26.0)	Sublobectomy	135 (20.0)	96 (20.4)	39 (19.2)	
Pneumonectomy      24 (3.6)      18 (3.8)      6 (3.0)        Reative      0.613        Relation      0.9      0.90 (6.1)      137 (67.5)        Yes      235 (34.9)      169 (35.9)      66 (32.5)        Chemotherapy      66 (32.5)      66 (32.5)        Chemotherapy      0.571      65 (33.1)      66 (30.5)        Yes      218 (32.3)      156 (63.31.1)      62 (30.5)        Yes      456 (67.7)      151 (66.9)      141 (69.5)        Natage      101 (21.4)      137 (67.5)      101 (21.4)        N1      137 (20.3)      101 (21.4)      36 (17.7)        N2      117 (17.4)      283 (60.1)      137 (67.5)      117 (21.6)        NPLN      137 (20.3)      101 (21.4)      30 (14.8)      118 (21.7)        N2      117 (17.4)      289 (61.4)      139 (68.5)      118 (21.7)        NPLN1      428 (63.5)      289 (61.4)      139 (68.5)      118 (21.7)        NPLN2      151 (22.4)      101 (23.4)      21 (20.2)      118 (21.7)        NPLN3      95 (14.1)      292 (62.0)      319 (68.5)	Lobectomy	515 (76.4)	357 (75.8)	158 (77.8)	
Radiation      0.451        No      439 (65.1)      302 (64.1)      137 (67.5)        Yes      235 (34.9)      169 (35.9)      66 (32.5)        Chemotherapy	Pneumonectomy	24 (3.6)	18 (3.8)	6 (3.0)	
No439 (65.1)302 (64.1)137 (67.5)Yes235 (34.9)169 (35.9)66 (32.5)Yes218 (32.3)156 (33.1)62 (30.5)Yes456 (67.7)315 (66.9)141 (69.5)Nage10.190N0420 (62.3)283 (60.1)37 (67.5)N1137 (20.3)101 (21.4)36 (17.7)N2117 (17.4)87 (18.5)30 (14.8)NPLN17 (20.3)110 (23.4)139 (68.5)NPLN151 (22.4)110 (23.4)41 (20.2)NPLN395 (14.1)72 (15.3)23 (11.3)LNR133 (63.9)99 (21.0)34 (16.7)LNR1133 (63.9)99 (21.0)34 (16.7)LNR2133 (19.7)99 (21.0)34 (16.7)LNR3110 (16.3)80 (17.0)30 (14.8)LDDDS1283 (48.7)25 (47.8)103 (50.7)LODDS3168 (24.9)117 (24.8)51 (22.1)LODDS3178 (26.4)129 (27.4)49 (24.1)	Radiation				0.451
Yes235 (34.9)169 (35.9) $66 (32.5)$ Chemotherapy0.571No218 (32.3)156 (33.1)62 (30.5)Yes456 (67.7)315 (66.9)141 (69.5)N stage0.190N0420 (62.3)283 (60.1)137 (67.5)N1137 (20.3)101 (21.4)36 (17.7)N2117 (74.9)87 (85.5)0.188NPLN0.19030 (48.5)0.188NPLN1428 (63.5)289 (61.4)139 (68.5)NPLN2151 (22.4)110 (23.4)41 (20.2)NPLN395 (14.1)292 (62.0)39 (68.5)LNR1431 (63.9)292 (62.0)39 (68.5)LNR2133 (19.7)99 (21.0)34 (16.7)LNR3110 (16.3)80 (17.0)30 (14.8)LODDS1288 (48.7)255 (47.8)103 (50.7)LODDS1168 (24.9)117 (24.8)51 (25.1)LODDS3178 (26.4)129 (27.4)49 (24.1)	No	439 (65.1)	302 (64.1)	137 (67.5)	
Chemotherapy      0.571        No      218 (32.3)      156 (33.1)      62 (30.5)        Yes      456 (67.7)      315 (66.9)      141 (69.5)        N stage	Yes	235 (34.9)	169 (35.9)	66 (32.5)	
No      218 (32.3)      15b (33.1)      62 (30.5)        Yes      456 (67.7)      315 (66.9)      141 (69.5)        N stage	Chemotherapy	21.0 (22.2)	15( (00.1)		0.571
Yes    315 (66.9)    141 (69.5)      N stage    0.190      N0    420 (62.3)    283 (60.1)    137 (67.5)      N1    137 (20.3)    101 (21.4)    36 (17.7)      N2    117 (17.4)    87 (18.5)    30 (14.8)      NPLN    0.188      NPLN1    428 (63.5)    289 (61.4)    139 (68.5)      NPLN2    151 (22.4)    100 (23.4)    41 (20.2)      NPLN3    95 (14.1)    72 (15.3)    23 (11.3)      LNR4    431 (63.9)    292 (62.0)    139 (68.5)      LNR1    431 (63.9)    292 (62.0)    139 (68.5)      LNR2    133 (19.7)    99 (21.0)    34 (16.7)      LNR3    110 (16.3)    80 (17.0)    30 (14.8)      LODDS    225 (47.8)    103 (50.7)    0.661      LODDS1    328 (48.7)    225 (47.8)    103 (50.7)      LODDS2    168 (24.9)    117 (24.8)    51 (25.1)      LODDS3    178 (26.4)    129 (27.4)    49 (24.1)	No	218 (32.3)	156 (33.1)	62 (30.5)	
N stage      0.190        N0      420 (62.3)      283 (60.1)      137 (67.5)        N1      137 (20.3)      101 (21.4)      36 (17.7)        N2      117 (17.4)      87 (18.5)      30 (14.8)        NPLN      117 (22.4)      110 (23.4)      41 (20.2)        NPLN3      95 (14.1)      72 (15.3)      23 (11.3)        NPLN3      95 (14.1)      99 (26.0)      139 (68.5)        LNR      133 (163.9)      292 (62.0)      139 (68.5)        LNR1      431 (63.9)      292 (62.0)      139 (68.5)        LNR2      133 (19.7)      99 (21.0)      34 (16.7)        LNR3      110 (16.3)      80 (17.0)      30 (14.8)        LODDS      0.661        LODDS1      328 (48.7)      225 (47.8)      103 (50.7)        LODDS2      168 (24.9)      117 (24.8)      51 (25.1)        LODDS3      178 (26.4)      129 (27.4)      49 (24.1)	i es	450 (07.7)	315 (00.9)	141 (09.5)	0.100
N0      420 (62.3)      283 (60.1)      137 (67.3)        N1      137 (20.3)      101 (21.4)      36 (17.7)        N2      117 (17.4)      87 (18.5)      30 (14.8)        NPLN        0.188        NPLN1      428 (63.5)      289 (61.4)      139 (68.5)        NPLN2      151 (22.4)      110 (23.4)      41 (20.2)        NPLN3      95 (14.1)      72 (15.3)      23 (11.3)        LNR      133 (63.9)      292 (62.0)      139 (68.5)        LNR1      431 (63.9)      292 (62.0)      139 (68.5)        LNR2      133 (19.7)      99 (21.0)      34 (16.7)        LNR3      110 (16.3)      80 (17.0)      30 (14.8)        LODDS        0.661        LODDS1      328 (48.7)      225 (47.8)      103 (50.7)        LODDS2      168 (24.9)      117 (24.8)      51 (25.1)        LODDS3      178 (26.4)      129 (27.4)      49 (24.1)	N stage	400 ((0.0)	000 ((0.1)		0.190
N1  157 (20.5)  101 (21.4)  36 (17.7)    N2  117 (17.4)  87 (18.5)  30 (14.8)    NPLN	NU	420 (62.3)	283 (60.1)	137 (67.5)	
N2  b)  b)  b)  b)    NPLN	N1 N2	137(20.3) 117(17.4)	101 (21.4)	30 (17.7)	
NPLN    0.166      NPLN    428 (63.5)    289 (61.4)    139 (68.5)      NPLN2    151 (22.4)    110 (23.4)    41 (20.2)      NPLN3    95 (14.1)    72 (15.3)    23 (11.3)      LNR    10 (23.4)    139 (68.5)      LNR1    431 (63.9)    292 (62.0)    139 (68.5)      LNR2    133 (19.7)    99 (21.0)    34 (16.7)      LNR3    100 (16.3)    80 (17.0)    30 (14.8)      LODDS    0.661      LODDS1    328 (48.7)    225 (47.8)    103 (50.7)      LODDS2    168 (24.9)    117 (24.8)    51 (25.1)      LODDS3    178 (26.4)    129 (27.4)    49 (24.1)	INZ NIDI N	117 (17.4)	87 (18.5)	50 (14.8)	0 1 9 9
NHAT  425 (60.5)  105 (60.5)    NPLN3  151 (22.4)  110 (23.4)  41 (20.2)    NPLN3  95 (14.1)  72 (15.3)  23 (11.3)    LNR  0.264    LNR1  431 (63.9)  292 (62.0)  139 (68.5)    LNR2  133 (19.7)  99 (21.0)  34 (16.7)    LNR3  110 (16.3)  80 (17.0)  30 (14.8)    LODDS  0.661    LODDS1  328 (48.7)  225 (47.8)  103 (50.7)    LODDS2  168 (24.9)  117 (24.8)  51 (25.1)    LODDS3  178 (26.4)  129 (27.4)  49 (24.1)	NPLN NDI N1	428 (63 5)	289 (61 4)	139 (68 5)	0.100
Initial  Initial  Initial    NPLN3  95 (14.1)  72 (15.3)  23 (11.3)    LNR	NPLN2	151 (22.4)	110 (23 4)	41 (20.2)	
LNR      0.264        LNR1      431 (63.9)      292 (62.0)      139 (68.5)        LNR2      133 (19.7)      99 (21.0)      34 (16.7)        LNR3      110 (16.3)      80 (17.0)      30 (14.8)        LODDS      0.661        LODDS1      328 (48.7)      225 (47.8)      103 (50.7)        LODDS2      168 (24.9)      117 (24.8)      51 (25.1)        LODDS3      178 (26.4)      129 (27.4)      49 (24.1)	NPLN3	95 (14.1)	72 (15 3)	23 (11.3)	
LNR1  431 (63.9)  292 (62.0)  139 (68.5)    LNR2  133 (19.7)  99 (21.0)  34 (16.7)    LNR3  110 (16.3)  80 (17.0)  30 (14.8)    LODDS  0.661    LODDS1  328 (48.7)  225 (47.8)  103 (50.7)    LODDS2  168 (24.9)  117 (24.8)  51 (25.1)    LODDS3  178 (26.4)  129 (27.4)  49 (24.1)	LNR		, 2 (1010)	20 (1110)	0 264
LNR2  133 (19.7)  99 (21.0)  34 (16.7)    LNR3  110 (16.3)  80 (17.0)  30 (14.8)    LODDS  0.661    LODDS1  328 (48.7)  225 (47.8)  103 (50.7)    LODDS2  168 (24.9)  117 (24.8)  51 (25.1)    LODDS3  178 (26.4)  129 (27.4)  49 (24.1)	LNR1	431 (63.9)	292 (62.0)	139 (68.5)	0.201
LNR3  110 (16.3)  80 (17.0)  30 (14.8)    LODDS  0.661    LODDS1  328 (48.7)  225 (47.8)  103 (50.7)    LODDS2  168 (24.9)  117 (24.8)  51 (25.1)    LODDS3  178 (26.4)  129 (27.4)  49 (24.1)	LNR2	133 (19.7)	99 (21.0)	34 (16.7)	
LODDS      0.661        LODDS1      328 (48.7)      225 (47.8)      103 (50.7)        LODDS2      168 (24.9)      117 (24.8)      51 (25.1)        LODDS3      178 (26.4)      129 (27.4)      49 (24.1)	LNR3	110 (16.3)	80 (17.0)	30 (14.8)	
LODDS1328 (48.7)225 (47.8)103 (50.7)LODDS2168 (24.9)117 (24.8)51 (25.1)LODDS3178 (26.4)129 (27.4)49 (24.1)	LODDS		()	(,	0.661
LODDS2      168 (24.9)      117 (24.8)      51 (25.1)        LODDS3      178 (26.4)      129 (27.4)      49 (24.1)	LODDS1	328 (48.7)	225 (47.8)	103 (50.7)	
LODDS3 178 (26.4) 129 (27.4) 49 (24.1)	LODDS2	168 (24.9)	117 (24.8)	51 (25.1)	
	LODDS3	178 (26.4)	129 (27.4)	49 (24.1)	

TNM, tumor-node-metastasis; SEER, stage Surveillance, Epidemiology, and End Results stage; NPLN, the number of positive lymph nodes; LNR, the lymph node ratio; LODDS, the log odds of positive lymph nodes.

#### 2.2. Variable calculation, grouping, and screening

The SEER database provides the number of dissected LNs (NDLN), number of positive LNs (NPLN), and N stage directly. The LNR is defined as NPLN divided by NDLN. LODDS is calculated according to the following formula: log ((NPLN+0.05)/(NDLN-NPLN+0.05)). The NPLN, LNR, and LODDS data were divided into three groups according to CSS using X-tile software (version 3.6.1; Yale University, New Haven, CT, USA). Finally, NPLN data were categorized into NPLN1 (range 0–0), NPLN2 (range 1–2), and NPLN3 (range 3–13) datasets. LNR data were categorized into LNR1 (range 0–0.02), LNR2 (range 0.03–0.30), and LNR3 (range 0.31–1.00) datasets. LODDS data were categorized into LODDS1 (–2.96–1.80), LODDS2 (–1.79–0.77), and LODDS3 (–0.76–2.15) datasets. The independent prognostic factors were screened by univariate and multivariate Cox proportional hazards regression models. The Kaplan-Meier survival and receiver operating characteristic (ROC) curves were conducted to access the effectiveness of the N stage, NPLNs, LNR, and LODDS in predicting the CSS.

## 2.3. Construction and validation of nomograms

The analyses showed that LODDS was the optimal LN scheme and performed better distinguishing and predicting ability than LNR, NPLN, and N stage. The study cohort was randomly divided into a training set and a testing set at a ratio of 7:3.

Univariate and multivariate Cox proportional hazards regression models were used to identify the independent prognostic factors, where CSS was the primary outcome. LODDS, age at diagnosis, race, sex, primary site, tumor size, nuclear grade, SEER stage, surgical methods, chemotherapy status, and radiation therapy status were all included in the multivariate analysis using the stepwise Akaike information criterion (AIC) method to identify the optimal final predictors. These factors, including LODDS, age at diagnosis, sex, tumor size, and radiation status, were included in the final models. Based on the multivariate Cox proportional hazards regression



**Fig. 2.** The ROC curves for predicting 1-, 3- and 5-year lung cancer-specific survival based on N stage (A), NPLN (B), LNR (C), and LODDS (D) in patients with SCLC. ROC, receiver operating characteristic curve; AUC, areas under the ROC curve; NPLN, the number of positive lymph nodes; LNR, the lymph node ratio; LODDS, the log odds of positive lymph nodes.



(caption on next page)

**Fig. 3.** The prognostic effect of N stage (A and B), NPLN (C and D), LNR (E and F), and LODDS (G and H) on the overall survival (A, C, E, and G) and lung cancer-specific survival (B, D, F, and H) of patients with SCLC. NPLN, the number of positive lymph nodes; LNR, the lymph node ratio; LODDS, the log odds of positive lymph nodes.

model, a novel nomogram was generated to predict the CSS in patients with SCLC using the "rms" package [23,24].

To test the discrimination ability and accuracy of the novel model, the ROC curves (area under the curve, AUC), decision curve analysis (DCA), and calibration plots were utilized in the training and testing sets. The AUC value was used to access the predictive ability of the nomogram. DCA plots were utilized to evaluate the clinical benefit of the nomogram. The net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated to compare the improvements of the novel model with the 8th TNM and SEER staging systems. The risk of patients in the training and testing cohorts was stratified based on the risk score of the nomogram. Kaplan-Maier curves were adopted to evaluate the discriminative power of the nomogram, TNM staging, and SEER staging.

### 2.4. Statistical analyses

All statistical analyses were performed using R software (version 4.1.2; USA) with two-sided tests, where P < 0.05 was considered statistically significant. In this study, "data.table", "survival", "timeROC", "survimer", "caret", "MASS", "rms", "rsconnect", "riskRegression", "ggpCA", "ggprism", "nricens", and "survIDINRI" R packages were used.

# 3. Results

## 3.1. Patient characteristics

A total of 674 SCLC patients were included in the final cohort of the study (Table 1). In this cohort, the majority of cases were in the early disease stages. In addition, there were more elderly patients and more patients with poorly differentiated tumors. Interestingly, 21.2% of cases were patients diagnosed with stage IIIA cancer. Lobectomy (76.4%) was the primary method of surgery for SCLC treatment, followed by sublobectomy (20%). Overall, 456 (67.7%) patients received chemotherapy, while only 235 (34.9%) patients received radiotherapy. Patients with lesions smaller than 3 cm or lesions located on the upper lobe were more likely to undergo surgery.

# 3.2. Screening of optimal LN schemes

Fig. 2(A-D) shows the predictive abilities of NPLN, LNR, LODDS, and N stage. The time-dependent one-, three-, and five-year AUC values for LODDS status were 0.69, 0.68, and 0.69, respectively. The time-dependent one-year AUC values for NPLN, LNR, and N stage were 0.65, 0.65, and 0.62, respectively. They were 0.64, 0.64, and 0.63 for the three-year AUC and 0.66, 0.65, and 0.64 for the five-year AUC, respectively. The Cox proportional hazards regression analysis and Kaplan-Meier curves were used to validate the discrimination ability of NPLN, LNR, LODDS, and N stage. The results showed that LODDS, NPLN, LNR, and N stage can be used as independent prognostic factors, but the LODDS status was able to better distinguish the three groups [Fig. 3(A-H), Table 2].

# Table 2

The univariate and multivariate Cox proportional hazards regression models and survival analysis of the different LNs schemes.

LNs status	No. Of cases	Univariate analysis	:	Multivariate analysis <sup>a</sup>		1-year survival rate	3-year survival rate	5-year survival rate
		HR (95% CIs)	P-value	HR (95% CIs)	P-value			
N stage								
NO	420 (62.3)	Reference		Reference		90.11%	69.33%	63.31%
N1	137 (20.3)	2.66 [2.04, 3.46]	< 0.001	2.70 [1.84, 3.98]	< 0.001	78.60%	37.45%	27.40%
N2	117 (17.4)	2.26 [1.70, 3.02]	< 0.001	2.11 [1.41, 3.16]	< 0.001	80.52%	45.09%	37.19%
NPLN								
NPLN1	428 (63.5)	Reference		Reference		90.29%	69.53%	63.54%
NPLN2	151 (22.4)	2.15 [1.66, 2.79]	< 0.001	2.18 [1.47, 3.22]	< 0.001	84.39%	44.30%	35.26%
NPLN3	95 (14.1)	3.50 [2.62, 4.68]	< 0.001	4.07 [2.67, 6.19]	< 0.001	69.41%	32.22%	22.55%
LNR								
LNR1	431 (63.9)	Reference		Reference		90.36%	69.19%	63.23%
LNR2	133 (19.7)	2.17 [1.64, 2.86]	< 0.001	2.20 [1.48, 3.28]	< 0.001	83.99%	46.37%	36.25%
LNR3	110 (16.3)	3.02 [2.30, 3.96]	< 0.001	3.31 [2.21, 4.95]	< 0.001	72.10%	32.87%	24.66%
LODDS								
LODDS1	328 (48.7)	Reference		Reference		93.87%	74.78%	67.86%
LODDS2	168 (24.9)	2.13 [1.59, 2.86]	< 0.001	2.10 [1.53, 2.88]	< 0.001	81.51%	52.32%	48.63%
LODDS3	178 (26.4)	3.67 [2.81, 4.80]	< 0.001	4.08 [2.80, 5.93]	< 0.001	76.05%	35.13%	24.46%
LODDS2 LODDS3	168 (24.9) 178 (26.4)	2.13 [1.59, 2.86] 3.67 [2.81, 4.80]	<0.001 <0.001	2.10 [1.53, 2.88] 4.08 [2.80, 5.93]	<0.001 <0.001	81.51% 76.05%	52.32% 35.13%	48.63% 24.46%

LNs, lymph nodes; NPLN, the number of positive lymph nodes; LNR, the lymph node ratio; LODDS, the log odds of positive lymph nodes. <sup>a</sup> The multivariate Cox proportional hazards regression models were adjusted by age, sex, race, location site, grade, tumor size, stage, surgery, radiation, and chemotherapy.

### C. Chao et al.

Nomogram construction and validation.

The whole cohort was randomly divided into the training (N = 471) and testing (N = 203) sets. First, the independent prognostic factors were identified using univariate and multivariate Cox proportional hazards regression models in the training set. LODDS status and age at diagnosis were the independent prognostic factors. After stepwise regression, five variables, including LODDS, age at diagnosis, sex, tumor size, and radiation therapy status, were utilized together to build a novel model with a minimal AIC value. Second, the "rms" package was used to plot a nomogram to predict the CSS for SCLC patients based on the five-variable multivariate Cox regression model (Fig. 4). Meanwhile, we developed a web-based version of the prognostic score calculator based on the nomogram. The web version of the nomogram (https://chaoce.shinyapps.io/DynNomapp\_LCSS/) was published online in order to facilitate its use. Meanwhile, we also developed a nomogram based on the log odds of positive lymph nodes to predict overall survival in patients with small cell lung cancer after surgery (Fig. S1) and this web version of nomogram was developed (https://chaoce.shinyapps.io/DynNomapp\_OS/).

Third, internal and external validation was performed to test the discrimination and stability of the nomogram. The AUC values of the nomogram in the training set were 0.76 (95% confidence interval (CI): 0.70–0.83), 0.72 (95%CI: 0.67–0.77), and 0.74 (95%CI: 0.68–0.79) for the one-, three- and five-year CSS, respectively. In the testing set, they were 0.76 (95%CI: 0.65–0.87), 0.73 (95%CI: 0.65–0.81), and 0.74 (95%CI: 0.65–0.82) for the one-, three- and five-year CSS, respectively [Fig. 6(A-F)]. The calibration curves proved a good agreement between actual and predicted survival conditions for the one-, three-, and five-year CSS. The calibration curves for the testing set had similar results [Fig. 5(A-F)].

# 3.3. Comparison among nomogram, TNM staging, and SEER staging

Compared to the SEER and TNM staging, DCA analysis suggested that the novel nomogram significantly increased the net benefits for almost all threshold probabilities in the training and testing sets [Fig. 7(A-F)]. Moreover, the NRI and IDI for the nomogram were



Fig. 4. A novel nomogram predicted 1-, 3- and 5-year lung cancer-specific survival for SCLC patients. LODDS, the log odds of positive lymph nodes.



Fig. 5. The calibration plots for predicting 1-, 3- and 5-year lung cancer-specific survival for SCLC patients in training set (A, B, and C) and testing set (D, E, and F).

calculated using TNM and SEER staging (Table 3). Compared to the TNM stage, the NRI values for the nomogram were 0.393 (95%CI: 0.192–0.500), 0.293 (95%CI: 0.207–0.427), and 0.307 (95%CI: 0.208–0.460) for the one-, three-, and five-year CSS in the training cohort, respectively. They were 0.478 (95%CI: 0.139–0.597), 0.243 (95%CI: 0.052–0.407), and 0.300 (95%CI: 0.116–0.462) for the one-, three-, and five-year CSS in the testing cohort, respectively. Compared to the SEER stage, the NRI values for the nomogram were 0.395 (95%CI: 0.230–0.526), 0.255 (95%CI: 0.122–0.391), and 0.275 (95%CI: 0.156–0.427) for the one-, three-, and five-year CSS in the training cohort, respectively. They were 0.374 (95%CI: 0.132–0.555), 0.289 (95%CI: 0.049–0.444), and 0.323 (95%CI: 0.100–0.450) for the one-, three-, and five-year CSS in the testing cohort, respectively. Similarly, the IDI values for the one-, three-, and five-year CSS were 0.075 (95%CI: 0.037–0.127), 0.110 (95%CI: 0.055–0.174), and 0.120 (95%CI: 0.066–0.186), respectively, compared to the SEER stage, and 0.069 (95%CI: 0.036–0.121), 0.116 (95%CI: 0.076–0.171), and 0.127 (95%CI: 0.081–0.185), respectively, compared to the TNM stage in the training cohort. In the testing cohort, the IDI values for the one-, three-, and five-year CSS were 0.062 (95%CI: 0.021–0.122), 0.101 (95%CI: 0.015–0.190), and 0.118 (95%CI: 0.031–0.213), respectively, compared to the SEER stage, and 0.057 (95%CI: 0.019–0.116), 0.091 (95%CI: 0.014–0.167), and 0.107 (95%CI: 0.023–0.189), respectively, compared to the TNM stage.

# 3.4. A novel risk stratification based on the nomogram

According to the total score calculated by the nomogram, the SCLC patients were divided into three groups as follows: nomo1 (-1.36-0.08), nomo2 (-0.07-0.66), and nomo3 (0.67-1.46). Compared to the SEER and TNM staging, the three nomo groups were able to better distinguish the SCLC patients using Kaplan-Meier curves [Fig. 8(A-L)].

## 4. Discussion

The LN status plays a vital role in the treatment and prognosis of the majority of solid tumors. In SCLC patients, surgery has been demonstrated to improve the local control rate [25]. With the gradual increase in the number of surgical patients, clinicians lack effective tools to evaluate patients with LN metastasis. Moreover, the VALSG and TNM staging systems have been shown to be inefficient in predicting the prognosis of SCLC patients [21]. The N stage can be used to determine the long-term survival of SCLC patients [26]. However, there is no prognostic significance between the N1 and N2 status. The accuracy of the N stage may be limited by the number of resected LNs, which is sometimes difficult to accomplish [26]. For NSCLC, multiple guidelines have provided



Fig. 6. The ROC curves for predicting 1-, 3- and 5-year lung cancer-specific survival based on the nomogram, TNM stage, and SEER stage in training set (A, B, and C) and testing set (D, E, and F). TNM, tumor-node-metastasis; SEER, the Surveillance, Epidemiology and End Results.

direction for an adequate nodal examination [27]: at least 10 LNs should be resected in early-stage NSCLC according to the American College of Surgeons Commission on Cancer, three mediastinal nodal stations are the minimum standard to remove according to the National Comprehensive Cancer Network, and three N1 and three mediastinal LNs should be removed based on the Union for International Cancer Control recommendations. However, only <40% of cases have met the current guidelines for the resected number of LNs [28]. Although LNR has shown a good effectiveness in predicting prognosis of resected SCLC patients [22], it cannot further stratify cases that have 0 or 1 NPLNs. Therefore, LODDS was introduced in order to assess LN metastasis in SCLC patients and to compare the predictive and discriminative ability of LNR, NPLN, and N stage. The LODDS stage can distinguish some N0 stage patients with poor prognosis. The present study demonstrated that LODDS was the optimal LN scheme to predict prognosis of SCLC patients and constructed a novel nomogram that was better distinguishing and predicting ability than the VALSG and TNM staging systems.

In the final model, LODDS, age at diagnosis, sex, tumor size, and radiotherapy status were utilized to assess the CSS in SCLC patients. The LODDS status was the most important factor in predicting CSS for SCLC patients, followed by age at diagnosis. In the existing studies, the TNM staging system contributed the most to predicting prognosis in SCLC patients [21,22,29,30]. However, the LN status did not contribute as much as the T stage, which may be due to inaccurate LN staging. This showed that the accurate LN status played an important role in increasing the discriminatory ability of the model. Elderly patients had a worse prognosis than young patients, likely due to worse tumor burden and degenerative changes [31]. Female patients had a better prognosis than male patients, which was consistent with previous studies [32]. In addition, smaller tumor size meant better survival, which has been confirmed by Wang et al. [33]. Early radiotherapy has been shown to be beneficial to the long-term prognosis of SCLC patients, while postoperative radiotherapy might be able to improve the survival benefit for high-risk patients [34,35].

A novel prognostic nomogram was generated based on the LODDS status for SCLC patients. Many researchers have focused on the construction of a prognostic evaluation for SCLC and have built nomograms related to it [21,22,29,30,36,37]. The majority of them have been used to predict the entire pan-stage of SCLC patients. For example, Wang et al. have created a nomogram with high prognostic accuracy based on eight factors, including the AJCC 8th TNM staging [29]. In addition, some researchers have built nomograms to predict long-term survival of particular patient groups, including SCLC patients with metastasis and combined SCLC patients [38,39]. To evaluate the efficacy of different treatments, nomograms can also be established to evaluate the survival of SCLC patients after radiotherapy, chemotherapy, or surgery [37,40,41]. So far, there have been three nomograms built to predict the overall survival of SCLC patients after surgery, where LODDS was not calculated and incorporated into the models. Wang et al. have built the first nomogram to predict the one-, three-, and five-year overall survival for SCLC patients that was better than TNM staging [21]. However, two types of N status, N stage, and LNR were included in the model, which was inconvenient for use in clinical work. Similarly, LN dissected and LN metastasis were both used to build a novel nomogram for SCLC [36]. In addition, Wu et al. have added



Fig. 7. The clinical decision curve analysis of nomogram, TNM stage, and SEER stage in prediction of 1-, 3- and 5-year lung cancer-specific survival from training set (A, B, and C) and testing set (D, E, and F). TNM, tumor-node-metastasis; SEER, the Surveillance, Epidemiology and End Results.

Table 3	
The NRI and IDI of the nomogram,	TNM stage, and SEER stage system in cancer-specific survival prediction for SCLC patients.

Index	Training set		Testing set	
	Estimate and 95% CI P-value		Estimate and 95% CI	P-value
NRI (vs. SEER Stage)				
1-year CSS	0.395 (0.230, 0.526)	< 0.001	0.374 (0.132, 0.555)	0.014
3-year CSS	0.255 (0.122, 0.391)	< 0.001	0.289 (0.049, 0.444)	0.024
5-year CSS	0.275 (0.156, 0.427)	< 0.001	0.323 (0.100, 0.450)	0.004
NRI (vs. TNM stage)				
1-year CSS	0.393 (0.192, 0.500)	< 0.001	0.478 (0.139, 0.597)	< 0.001
3-year CSS	0.293 (0.207, 0.427)	< 0.001	0.243 (0.052, 0.407)	0.016
5-year CSS	0.307 (0.208, 0.460)	< 0.001	0.300 (0.116, 0.462)	0.010
IDI (vs. SEER Stage)				
1-year CSS	0.075 (0.037, 0.127)	< 0.001	0.062 (0.021, 0.122)	0.004
3-year CSS	0.110 (0.055, 0.174)	< 0.001	0.101 (0.015, 0.190)	0.026
5-year CSS	0.120 (0.066, 0.186)	< 0.001	0.118 (0.031, 0.213)	0.002
IDI (vs. TNM Stage)				
1-year CSS	0.069 (0.036, 0.121)	< 0.001	0.057 (0.019, 0.116)	< 0.001
3-year CSS	0.116 (0.076, 0.171)	< 0.001	0.091 (0.014, 0.167)	0.024
5-year CSS	0.127 (0.081, 0.185)	<0.001	0.107 (0.023, 0.189)	0.008

NRI, net reclassification improvement; IDI, integrated discrimination improvement; SCLC, small cell lung cancer; CI, confidence interval; SEER, stage Surveillance, Epidemiology, and End Results stage; TNM, tumor-node-metastasis; CSS, cancer-specific survival.

age, sex, and LNR to the new model based on the AJCC 8th TNM staging, although their AUC value was not high enough [37]. The present model did not utilize TNM staging data in the nomogram, but its accuracy was better than that of TNM staging. It was speculated that the TNM staging is only suitable for evaluating patients before surgery, while a nomogram is more appropriate for predicting long-term survival after surgery. Last but not least, for convenience of clinicians, we developed a web-based tool via 'DynNom' package, which could easily show the predicting survival rate across time by inputting corresponding clinical features. For example, a 60-year-old woman with small cell lung cancer, no radiotherapy, a lesion less than 3 cm, and lymph node stage LODDS1 had a 5-year survival rate of 0.8 (0.74, 0.87).



Fig. 8. The Kaplan-Maier survival curves of overall survival and the lung cancer-specific survival based on the nomogram (A, B, C, and D), TNM stage (E, F, G, and H), and SEER stage (I, J, K, and L) in training set and testing set. TNM, tumor-node-metastasis; SEER, the Surveillance, Epidemiology and End Results.

Nevertheless, there were some limitations in the present study. First, smoking index has been shown to be an independent prognostic factor and has been incorporated into some nomograms to predict survival [42]. However, the present study database lacked data related to smoking. Second, tumor markers were also important indicators. For example, neuron-specific enolase is a specific marker for SCLC. Xie et al. and Pan et al. have built a nomogram with high prognostic accuracy using these variables [30,43]. In addition, Naples Prognostic Score is calculated based on nutritional and inflammatory status and is an independent prognostic factor [44]. However, the SEER database do not include there associated data. Third, chemotherapy is the basic treatment for SCLC, but the present model did not consider it due to the lack of detailed chemotherapy protocols. Last but not least, this model has not been validated by local clinical data. In our hospital, small cell lung cancer patients are rarely operated on and it is difficult to collect sufficient clinical data. It is expected that more SCLC patients will benefit from surgery and more accurate clinical prediction models will be developed.

# 5. Conclusions

In conclusion, LODDS was the optimal LN scheme for predicting CSS in SCLC patients after surgery and had a greater ability to recognize the high-risk population after surgery, especially for stage N0 patients. A novel nomogram based on LODDS, age, sex, tumor size, and radiotherapy status was built to predict CSS for SCLC patients after surgery. Internal and external validation both confirmed its predictive accuracy, reliability, and clinical applicability, which were better than those for TNM and SEER staging.

## **Ethics statement**

The data was derived from the SEER database, it was unnecessary to obtain patient consent again.

## **Consent for publication**

Not applicable.

#### Author contribution statement

Ce Chao: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Bin Wang; Dongmei Di: Conceived and designed the experiments.

Kun Mei: Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Min Wang; Renzhe Tang; Yongxiang Qian: Contributed reagents, materials, analysis tools or data; Analyzed and interpreted the data.

### **Funding statement**

The study was supported by The Young Talent Development Plan of Changzhou Health Commission (CZQM2020004, CZQM2020034), Basic Research Project of Changzhou Science and Technology Bureau (CJ20200104), Social Development Projects of Changzhou science and Technology Bureau (CE20205039), Young talents Science and Technology project of Changzhou Health Commission (QN201913), and Science and Technology Project of Changzhou Health Commission (WZ202106).

# Data availability statement

Data were from a public database.

# Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

# Acknowledgments

We thank International Science Editing (http://www.internationalscienceediting.com) for editing this manuscript.

# Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2023.e18502.

# Abbreviations

LN	lymph node
LNR	lymph node ratio
SCLC	small cell lung cancer
NPLNs	number of positive LNs
LODDS	log odds of positive LNs
CSS	cancer-specific survival
ROC	receiver operating characteristic curves
SEER	the Surveillance Epidemiology and End Results database
DCA	decision curve analysis
VALSG	the Veterans Administration Lung Study Group
TNM	tumor–node–metastasis
AIC	Akaike information criterion
NRI	net reclassification improvement
IDI	integrated discrimination improvement

## References

- H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca - Cancer J. Clin. 71 (2021) 209–249, https://doi.org/10.3322/caac.21660.
- [2] S. Wang, S. Zimmermann, K. Parikh, A.S. Mansfield, A.A. Adjei, Current diagnosis and management of small-cell lung cancer, Mayo Clin. Proc. 94 (2019) 1599–1622, https://doi.org/10.1016/j.mayocp.2019.01.034.
- [3] M.G. Raso, N. Bota-Rabassedas, Wistuba II, Pathology and classification of SCLC, Cancers 13 (2021), https://doi.org/10.3390/cancers13040820.
- [4] M. Yuan, Y. Zhao, H.T. Arkenau, T. Lao, L. Chu, Q. Xu, Signal pathways and precision therapy of small-cell lung cancer, Signal Transduct. Targeted Ther. 7 (2022) 187, https://doi.org/10.1038/s41392-022-01013-y.
- [5] C.L. Hann, C.M. Rudin, Management of small-cell lung cancer: incremental changes but hope for the future, Oncology (Williston Park) 22 (2008) 1486–1492.

- [6] F. Doerr, S. Stange, M. Michel, G. Schlachtenberger, H. Menghesha, T. Wahlers, K. Hekmat, M.B. Heldwein, Stage I and II small-cell lung cancer-new challenge for surgery, Lung 200 (2022) 505–512, https://doi.org/10.1007/s00408-022-00549-8.
- [7] M. Casiraghi, G. Sedda, E. Del Signore, G. Piperno, P. Maisonneuve, F. Petrella, F. de Marinis, L. Spaggiari, Surgery for small cell lung cancer: when and how, Lung Cancer 152 (2021) 71–77, https://doi.org/10.1016/j.lungcan.2020.12.006.
- [8] Y. Chai, Y. Ma, W. Feng, H. Lu, L. Jin, Effect of surgery on survival in patients with stage III N2 small cell lung cancer: propensity score matching analysis and nomogram development and validation, World J. Surg. Oncol. 19 (2021) 258, https://doi.org/10.1186/s12957-021-02364-6.
- [9] L. Gao, L. Shen, K. Wang, S. Lu, Propensity score matched analysis for the role of surgery in stage small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital, Lung Cancer 162 (2021) 54–60, https://doi.org/10.1016/j. lungcan.2021.10.009.
- [10] C.J. Yang, D.Y. Chan, S.A. Shah, B.A. Yerokun, X.F. Wang, T.A. D'Amico, M.F. Berry, D.H. Harpole Jr., Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer, Ann. Surg. 268 (2018) 1105–1112, https://doi.org/10.1097/SLA.00000000002287.
- [11] E. Wakeam, S.A. Acuna, N.B. Leighl, M.E. Giuliani, S.R.G. Finlayson, T.K. Varghese, G.E. Darling, Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival, Lung Cancer 109 (2017) 78–88, https://doi.org/10.1016/j. lungcan 2017 04 021
- [12] B.W. Carter, B.S. Glisson, M.T. Truong, J.J. Erasmus, Small cell lung carcinoma: staging, imaging, and treatment considerations, Radiographics 34 (2014) 1707–1721, https://doi.org/10.1148/rg.346140178.
- [13] A.G. Nicholson, K. Chansky, J. Crowley, R. Beyruti, K. Kubota, A. Turrisi, W.E. Eberhardt, J. van Meerbeeck, R. Rami-Porta, Staging, prognostic factors committee AB, participating I, staging, prognostic factors committee advisory B, participating I. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer, J. Thorac. Oncol. 11 (2016) 300–311, https://doi.org/10.1016/j.jtho.2015.10.008.
- [14] X. Cheng, W. Zeng, Y. Liu, Z. Song, Y. Han, Q. Luo, S. Lu, Impact of lymph node dissection on survival and tumor recurrence for patients with resected cT1-2N0 small cell lung cancer, Ann. Surg Oncol. 29 (2022) 7512–7525, https://doi.org/10.1245/s10434-022-12215-7.
- [15] J. Tang, S. Jiang, L. Gao, X. Xi, R. Zhao, X. Lai, B. Zhang, Y. Jiang, Construction and validation of a nomogram based on the log odds of positive lymph nodes to predict the prognosis of medullary thyroid carcinoma after surgery, Ann. Surg Oncol. 28 (2021) 4360–4370, https://doi.org/10.1245/s10434-020-09567-3.
- [16] Y. Yu, P. Zhang, R. Yao, J. Wang, P. Wang, X. Xue, J. Xiao, Z. Wang, Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study, Transl. Lung Cancer Res. 9 (2020) 1285–1301, https://doi.org/10.21037/tlcr-20-193.
- [17] N.C. Lin, I.H. Su, J.T. Hsu, Y.J. Chang, K.Y. Tsai, Comparison of different lymph node staging systems in patients with positive lymph nodes in oral squamous cell carcinoma, Oral Oncol. 114 (2021), 105146, https://doi.org/10.1016/j.oraloncology.2020.105146.
- [18] J. Wen, J. Chen, D. Chen, S.K. Jabbour, T. Xue, X. Guo, H. Ma, F. Ye, Y. Mao, J. Shu, Y. Liu, X. Lu, Z. Zhang, Y. Chen, M. Fan, Comprehensive analysis of prognostic value of lymph node classifications in esophageal squamous cell carcinoma: a large real-world multicenter study, Ther Adv Med Oncol 13 (2021), 17588359211054895, https://doi.org/10.1177/17588359211054895.
- [19] D. Prassas, S.A. Safi, M.C. Stylianidi, L.A. Telan, S. Krieg, C. Roderburg, I. Esposito, T. Luedde, W.T. Knoefel, A.N. Krieg, LNR or LODDS: which is the most appropriate lymph node classification scheme for patients with radically resected pancreatic cancer? Cancers 14 (2022) https://doi.org/10.3390/ cancers14071834.
- [20] C. Chen, Z. Rui, W. Yuhan, Z. Yongjie, Q. Yinghe, Y. Ning, S. Tianqiang, L. Jianying, L. Jiangtao, M. Xianhai, L. Shengping, S. Shubin, C. Zhiqiang, T. Zhaohui, G. Zhimin, Optimal lymph node staging system in evaluating prognosis of gallbladder carcinoma: a multi-institutional study, Ann. Surg Oncol. 28 (2021) 8142–8151, https://doi.org/10.1245/s10434-021-10749-w.
- [21] Y. Wang, Z. Pang, X. Chen, T. Yan, J. Liu, J. Du, Development and validation of a prognostic model of resectable small-cell lung cancer: a large population-based cohort study and external validation, J. Transl. Med. 18 (2020) 237, https://doi.org/10.1186/s12967-020-02412-x.
- [22] H. Yang, T. Mei, The prognostic value of lymph node ratio in patients with surgically resected stage I-III small-cell lung cancer: a propensity score matching analysis of the SEER database, Eur. J. Cardio. Thorac. Surg. 60 (2021) 1212–1220, https://doi.org/10.1093/ejcts/ezab287.
- [23] Y.H. Liu, L.L. Wu, J.Y. Qian, Z.X. Li, M.X. Shi, Z.R. Wang, L.Y. Xie, Y. Liu, D. Xie, W.J. Cao, A nomogram based on atelectasis/obstructive pneumonitis could predict the metastasis of lymph nodes and postoperative survival of pathological N0 classification in non-small cell lung cancer patients, Biomedicines 11 (2023), https://doi.org/10.3390/biomedicines11020333.
- [24] S.J. Yoon, B. Park, J. Kwon, C.S. Lim, Y.C. Shin, W. Jung, S.H. Shin, J.S. Heo, I.W. Han, Development of nomograms for predicting prognosis of pancreatic cancer after pancreatectomy: a multicenter study, Biomedicines 10 (2022), https://doi.org/10.3390/biomedicines10061341.
- [25] M. Anraku, T.K. Waddell, Surgery for small-cell lung cancer, Semin. Thorac. Cardiovasc. Surg. 18 (2006) 211–216, https://doi.org/10.1053/j.
- semtcvs.2006.08.006.
  [26] A.J. Rucker, V. Raman, O.K. Jawitz, S.L. Voigt, B.C. Tong, T.A. D'Amico, D.H. Harpole, Effect of lymph node assessment on outcomes in surgery for limited stage small cell lung cancer, Ann. Thorac. Surg. 110 (2020) 1854–1860, https://doi.org/10.1016/j.athoracsur.2020.04.117.
- [27] K.S. Tan, M. Hsu, P.S. Adusumilli, Pathologic node-negative lung cancer: adequacy of lymph node yield and a tool to assess the risk of occult nodal disease, Lung Cancer 174 (2022) 60–66, https://doi.org/10.1016/j.lungcan.2022.10.004.
- [28] M.P. Smeltzer, N.R. Faris, M.A. Ray, R.U. Osarogiagbon, Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent, JAMA Oncol. 4 (2018) 80–87, https://doi.org/10.1001/jamaoncol.2017.2993.
- [29] S. Wang, L. Yang, B. Ci, M. Maclean, D.E. Gerber, G. Xiao, Y. Xie, Development and validation of a nomogram prognostic model for SCLC patients, J. Thorac. Oncol. 13 (2018) 1338–1348, https://doi.org/10.1016/j.jtho.2018.05.037.
- [30] H. Pan, X. Shi, D. Xiao, J. He, Y. Zhang, W. Liang, Z. Zhao, Z. Guo, X. Zou, J. Zhang, J. He, Nomogram prediction for the survival of the patients with small cell lung cancer, J. Thorac. Dis. 9 (2017) 507–518, https://doi.org/10.21037/jtd.2017.03.121.
- [31] M.J. Aarts, J.G. Aerts, B.E. van den Borne, B. Biesma, V.E. Lemmens, J.S. Kloover, Comorbidity in patients with small-cell lung cancer: trends and prognostic impact, Clin. Lung Cancer 16 (2015) 282–291, https://doi.org/10.1016/j.cllc.2014.12.003.
- [32] J.H. Lim, J.S. Ryu, J.H. Kim, H.J. Kim, D. Lee, Gender as an independent prognostic factor in small-cell lung cancer: inha Lung Cancer Cohort study using propensity score matching, PLoS One 13 (2018), e0208492, https://doi.org/10.1371/journal.pone.0208492.
- [33] L. Wang, X. Dou, T. Liu, W. Lu, Y. Ma, Y. Yang, Tumor size and lymph node metastasis are prognostic markers of small cell lung cancer in a Chinese population, Medicine (Baltim.) 97 (2018), e11712, https://doi.org/10.1097/MD.00000000011712.
- [34] W.S. Liu, L.J. Zhao, S. Wang, L.L. Gong, Z.Y. Liu, Z.Y. Yuan, P. Wang, Benefits of postoperative radiotherapy in multimodality treatment of resected small-cell lung cancer with lymph node metastasis, Eur. J. Surg. Oncol. 40 (2014) 1156–1162, https://doi.org/10.1016/j.ejso.2014.02.232.
- [35] J. Li, Z. Zeng, Z. Huang, Y. Gong, C. Xie, Additional postoperative radiotherapy prolonged the survival of patients with I-iia small cell lung cancer: analysis of the SEER database, JAMA Oncol. 2022 (2022), 6280538, https://doi.org/10.1155/2022/6280538.
- [36] Q. Zeng, J. Li, F. Tan, N. Sun, Y. Mao, Y. Gao, Q. Xue, S. Gao, J. Zhao, J. He, Development and validation of a nomogram prognostic model for resected limitedstage small cell lung cancer patients, Ann. Surg Oncol. 28 (2021) 4893–4904, https://doi.org/10.1245/s10434-020-09552-w.
- [37] L.L. Wu, W.T. Chen, C.W. Li, S.H. Song, S.Q. Xu, S.P. Wan, Z.Y. Liu, W.K. Lin, K. Li, Z.X. Li, D. Xie, The construction and validation of nomogram to predict the prognosis with small-cell lung cancer followed surgery, Cancers 14 (2022), https://doi.org/10.3390/cancers14153723.
- [38] L. Yang, Y. Zhou, G. Wang, D. Liu, B. Chen, D. Pu, P. Correale, D. Rades, Y. Tomita, A. Inno, M. Santarpia, Y. Li, W. Li, Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database, Transl. Lung Cancer Res. 10 (2021) 4250–4265, https://doi.org/10.21037/tlcr-21-804.
- [39] Q. Shan, J. Shi, X. Wang, J. Guo, X. Han, Z. Wang, H. Wang, A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study, BMC Cancer 21 (2021) 640, https://doi.org/10.1186/s12885-021-08384-5.
- [40] M. Liang, M. Chen, S. Singh, S. Singh, Prognostic nomogram for overall survival in small cell lung cancer patients treated with chemotherapy: a SEER-based retrospective cohort study, Adv. Ther. 39 (2022) 346–359, https://doi.org/10.1007/s12325-021-01974-6.

- [41] X. Yuan, Z. Zheng, F. Liu, Y. Gao, W. Zhang, R. Berardi, P. Mohindra, Z. Zhu, J. Lin, Q. Chu, A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy, Transl. Lung Cancer Res. 10 (2021) 2163–2171, https://doi.org/ 10.21037/tlcr-21-211.
- [42] C. Zeng, N. Li, F. Li, P. Zhang, K. Wu, D. Liu, S. Zhao, Prognostic factors of patients with small cell lung cancer after surgical treatment, Ann. Transl. Med. 9 (2021) 1146, https://doi.org/10.21037/atm-21-2912.
- [43] D. Xie, R. Marks, M. Zhang, G. Jiang, A. Jatoi, Y.I. Garces, A. Mansfield, J. Molina, P. Yang, Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers, J. Thorac. Oncol. 10 (2015) 1213–1220, https://doi.org/10.1097/JTO.00000000000585.
- [44] S. Chen, S. Liu, S. Xu, S. Cao, Z. Han, L. Kong, D. Ren, G. Duan, Naples prognostic score is an independent prognostic factor in patients with small cell lung cancer and nomogram predictive model established, J. Inflamm. Res. 15 (2022) 3719–3731, https://doi.org/10.2147/JIR.S371545.